Endo Pharmaceuticals Announces First Patient Enrolled in Second Phase III Clinical Trial of Urocidin

Endo Pharmaceuticals ENDP and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin. The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to compare Urocidin™ with mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscle-invasive bladder cancer.